Print this page
-
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL).
Protocol: 111803Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Any Site -
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas.
Protocol: 141905Principal Investigator:
- Pankaj Agarwalla (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer.
Protocol: 052001Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Breast -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Liver
Any Site
Other Digestive Organ -
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).
Protocol: 032002Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE).
Protocol: 072006Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Anus